29 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00821 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | NCI-H460 | Human lung adenocarcinoma | MIC : 10−4 to 10−9 M |
| dbacp00822 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | MB435s | Human breast carcinoma | MIC : 10−4 to 10−9 M |
| dbacp00823 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | MCF-7 | Non-tumourigenic mammary gland cancer | MIC : 10−4 to 10−9 M |
| dbacp00824 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | PC-3 | Human prostate carcinoma | MIC : 10−4 to 10−9 M |
| dbacp00829 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | NCI-H460 | Human lung adenocarcinoma | MIC : 10−4 to 10−9 M |
| dbacp00830 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | MB435s | Human breast carcinoma | MIC : 10−4 to 10−9 M |
| dbacp00831 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | MCF-7 | Non-tumourigenic mammary gland cancer | MIC : 10−4 to 10−9 M |
| dbacp00832 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | PC-3 | Human prostate carcinoma | MIC : 10−4 to 10−9 M |
| dbacp02659 | Dermaseptin-B3 | ALWKnMLKGIGKLAGQAALGAVKTLVGAE | Giant leaf frog | Membrane lysis | In vitro proliferation assay, Soft agar assay | PC-3 | Human epithelial prostate adenocarcinoma | EC50 : 2 μM |
| dbacp02779 | Distinctin-Like-Peptide-PH | NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN | Skin Secretion, Northern orange-legged leaf frog, South America | Membrane lysis via pore formation | MTT Cell viability assay, LDH assay | H157 | Prostate carcinoma | MIC : ≥ 4.197 μM |
| dbacp02780 | Distinctin-Like-Peptide-PH | NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN | Skin Secretion, Northern orange-legged leaf frog, South America | Membrane lysis via pore formation | MTT Cell viability assay, LDH assay | H158 | Prostate carcinoma | IC50 : 15.41 μg/mL |
| dbacp02781 | Distinctin-Like-Peptide-PH | NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN | Skin Secretion, Northern orange-legged leaf frog, South America | Membrane lysis via pore formation | MTT Cell viability assay, LDH assay | PC3 | Lung cancer | MIC : ≥ 4.197 μM |
| dbacp02782 | Distinctin-Like-Peptide-PH | NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN | Skin Secretion, Northern orange-legged leaf frog, South America | Membrane lysis via pore formation | MTT Cell viability assay, LDH assay | PC3 | Lung cancer | IC50 : 32.25 μg/mL |
| dbacp02826 | EGFR-lytic | YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK | Synthetic Peptide | Cell membrane lysis | ELISA | MDA-MB-231 | Breast cancer | IC50 : 0.12 µM |
| dbacp02827 | EGFR-lytic | YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK | Synthetic Peptide | Cell membrane lysis | ELISA | MDA-MB-231 | Breast cancer | IC50 : 0.46 µM |
| dbacp04592 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | Hela | Human cervical cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04593 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | SACC-83 | Human salivary adenoid cystic carcinoma | IC50 : 27.9 μM - 283.3 μM |
| dbacp04594 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | HepG2 | Human liver cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04595 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | PC-3 | Human Prostate cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp06737 | Aurein 1.2_mutant (Aurm) | GLFDIIKKIIKSF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | SW-480 | Colon Cancer | 51.63% cell viability |
| dbacp06738 | Aurein 1.2_mutant (Aurm) | GLFDIIKKIIKSF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | HT-29 | Colon Cancer | 66.10% cell viability |
| dbacp06739 | Aurein 1.2_R5 (R5-Aur) | RRRRRGLFDIIKKIAESF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | SW-480 | Colon Cancer | 43.89% cell viability |
| dbacp06740 | Aurein 1.2_R5 (R5-Aur) | RRRRRGLFDIIKKIAESF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | HT-29 | Colon Cancer | 61.56% cell viability |
| dbacp06741 | Aurein 1.2_mutant_R5 (R5-Aurm) | RRRRRGLFDIIKKIIKSF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | SW-480 | Colon Cancer | 40.62% cell viability |
| dbacp06742 | Aurein 1.2_mutant_R5 (R5-Aurm) | RRRRRGLFDIIKKIIKSF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | HT-29 | Colon Cancer | 54.22% cell viability |
| dbacp07339 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | A-549 | Lung Cancer | IC50 = 4.5 µM |
| dbacp07340 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | CT-26 | Colorectal Cancer | IC50 = 2.2 µM |
| dbacp07341 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | MDA-MB-435 WT | Breast Cancer | IC50 = 3.5 µM |
| dbacp07342 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | MDA-MB-435 DOX-R | Breast Cancer | IC50 = 3.4 µM |